18F-AV-133
Drug185 MBq
NCT Number: NCT01503944
The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control subjects.
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Phase 1 / Phase 2
Research Site, Sun City, Arizona, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
DLB:
Inclusion criteria
AD:
Inclusion criteria
PD:
Normal subjects:
Exclusion criteria
185 MBq
185-370 MBq
Time frame: Four Weeks
The ratio of tracer activity in striatal target areas of interest relative to the occipital cortex reference region
Time frame: Four Weeks
The ratio of tracer activity in cortical target areas of interest relative to the cerebellum reference region
Avid Radiopharmaceuticals
Industry
Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01208675
Alzheimer Disease, Alzheimer's Disease
Ängelholm, Sweden
View Trial DetailsNCT06445465
Alpha-Synucleinopathy, Autonomic Nervous System Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT04939818
Alzheimer Disease, Amyotrophic Lateral Sclerosis
London, Greater London, United Kingdom
View Trial DetailsNCT02910102
Alzheimer Disease, Alzheimer's Disease
Phoenix, Arizona, United States
View Trial Details